AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)
- Skyrizi revenue 4.48bln, Rinvoq estimate 2.12bln
- Humira revenue 688mln.
- Adj. GM 83.6%.
Context
AbbVie reported Q1 2026 earnings that beat expectations with an adjusted EPS of 2.65 compared to the expected 2.59 and revenue of 15 billion, surpassing the forecast of 14.72 billion. The strong performance, reinforced by robust contributions from Skyrizi and Rinvoq, suggests resilience in AbbVie's portfolio, which could enhance confidence in the stock and its forward guidance.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ABBVIE INC#ABBV.US#GENERAL MOTORS CO#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#AUTOMOBILE MANUFACTURERS#BIOTECHNOLOGY#METALS & MINING#AUTOMOBILES#BIOTECHNOLOGY (GROUP)#AUTOMOBILES & COMPONENTS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#GM#DXY#US EQUITIES